{
  "id": 13100030,
  "title": "TRex Bio prices $117M IPO to support immune drug work",
  "url": "https://urgent.news/2026/10/09/trex-bio-prices-117m-ipo-to-support-immune-drug-work",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T10:59:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/trex-bio-ipo-pricing-autoimmune-tregs/832297/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}